200 related articles for article (PubMed ID: 11896595)
1. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
[TBL] [Abstract][Full Text] [Related]
2. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
3. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
Inga A; Monti P; Fronza G; Darden T; Resnick MA
Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
5. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
6. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
7. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
8. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
9. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
Smith PD; Crossland S; Parker G; Osin P; Brooks L; Waller J; Philp E; Crompton MR; Gusterson BA; Allday MJ; Crook T
Oncogene; 1999 Apr; 18(15):2451-9. PubMed ID: 10229196
[TBL] [Abstract][Full Text] [Related]
10. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes.
Thornborrow EC; Patel S; Mastropietro AE; Schwartzfarb EM; Manfredi JJ
Oncogene; 2002 Feb; 21(7):990-9. PubMed ID: 11850816
[TBL] [Abstract][Full Text] [Related]
11. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast.
Flaman JM; Robert V; Lenglet S; Moreau V; Iggo R; Frebourg T
Oncogene; 1998 Mar; 16(10):1369-72. PubMed ID: 9546439
[TBL] [Abstract][Full Text] [Related]
12. Gain-of-function mutations in the tumor suppressor gene p53.
van Oijen MG; Slootweg PJ
Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.
Miller CW; Chumakov A; Said J; Chen DL; Aslo A; Koeffler HP
Oncogene; 1993 Jul; 8(7):1815-24. PubMed ID: 8510927
[TBL] [Abstract][Full Text] [Related]
14. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles.
Rand A; Glenn KS; Alvares CP; White MB; Thibodeau SM; Karnes WE
Cancer Lett; 1996 Jan; 98(2):183-91. PubMed ID: 8556707
[TBL] [Abstract][Full Text] [Related]
15. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
[TBL] [Abstract][Full Text] [Related]
17. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.
Dearth LR; Qian H; Wang T; Baroni TE; Zeng J; Chen SW; Yi SY; Brachmann RK
Carcinogenesis; 2007 Feb; 28(2):289-98. PubMed ID: 16861262
[TBL] [Abstract][Full Text] [Related]
18. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
[TBL] [Abstract][Full Text] [Related]
19. p53 mutants without a functional tetramerisation domain are not oncogenic.
Chène P; Bechter E
J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
[TBL] [Abstract][Full Text] [Related]
20. Dominant-negative p53 mutations in rheumatoid arthritis.
Han Z; Boyle DL; Shi Y; Green DR; Firestein GS
Arthritis Rheum; 1999 Jun; 42(6):1088-92. PubMed ID: 10366100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]